

Scientific Program

BIOCHEMISTRY/MOLECULAR ONCOLOGY

Room A, 09:00-11:00

Thursday, September 20

Chair Persons: P.E. Nielsen, H.M. Said

116. Drug delivery by peptide conjugation. **P.E. Nielsen** (Copenhagen, Denmark) (30')
249. Experimental regulation of natural plant extracts in human cancer disease induced gene expression. **H.M. Said** (Izmir, Turkey) (25')
171. Insight into the interplay between metabolism of sarcosine and calmodulin-dependent signalling in prostate cells. **V. Strmiska**, P. Michalek, S. Krizkova, R. Guran, O. Zitka, H. Sturikova, O. Krystofova, D. Sterbova, V. Adam, Z. Heger (Brno, Czech Republic) (25')
191. Impact of *O*-GlcNAcylation over the PI3-kinase/Akt pathway in oral squamous cell cancer. **D. Illescas Barbosa**, V. Jiménez Castillo, H. Sánchez Martínez, C. Díaz Hernández, A. Torres Rivera, B.X. Ávila Curiel, A. Rodríguez Moreno, T. Lefebvre, M. Mortuaire, C.J. Solórzano Mata (Oaxaca, Mexico; Lille, France) (25')
103. Molecular markers of therapy response in breast cancer. **B. Gyórfy**, J. Fekete (Budapest, Hungary) (15')

EXPERIMENTAL THERAPEUTICS

Room A, 11:30-13:00

Thursday, September 20

Chair Persons: M. Acevedo-Duncan, N.T. Telang

101. Preclinical testing of 5-amino-1-((1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-carboxamide (ICA-1); a potent Protein kinase C- α inhibitor as a potential anticancer drug. C. Apostolatos, A. Apostolatos, W.S. Ratnayake, M. Bourgeois, **M. Acevedo-Duncan** (Tampa, FL, USA) (25')
106. Drug resistant breast and colon cancer stem cells: Targeted approach for stem cell therapy. **N.T. Telang** (Montvale, NJ, USA) (25')
216. Biomarkers of radio-sensitivity and radio-resistance. **R. Di Pietro** (Chieti, Italy) (20')
108. Recent clinical observations and molecular mechanism findings indicate dicycloplatin is an effective drug in cancer chemotherapy with bearable side effects. **J.J. Yu**, M.D. Mueller (Morgantown, WV, USA) (20')

CANCER THERAPEUTICS

Room A, 16:00-17:30
Thursday, September 20

Chair Persons: Y. Suzuki-Karasaki, N. Eliopoulos

128. Cold atmospheric plasma (CAP)-stimulated transfusion (PLAST): A novel CAP-based anticancer agent. **Y. Suzuki-Karasaki** (Nasushiobara; Tokyo, Japan) (20')
129. Critical regulatory role of reactive oxygen/nitrogen species (RONS) in the antitumor activity of cold plasma-stimulated transfusion (PLAST). **M. Suzuki-Karasaki**, M. Suzuki-Karasaki, H. Miyahara, T. Ochiai, Y. Suzuki-Karasaki (Nasushiobara; Tokyo; Yokohama, Japan) (15')
109. Cold plasma-stimulated transfusion (PLAST) induces necroptosis in murine and human osteosarcoma cell lines. **T. Ando**, M. Suzuki-Karasaki, H. Haro, Y. Suzuki-Karasaki (Yamanashi; Tochigi; Tokyo, Japan) (15')
225. Use of mesenchymal stem cells for protection of kidney cells against cisplatin toxicity. **N. Eliopoulos** (Montreal, Canada) (20')
194. Inhibitory effects of BMP9 on the bone metastasis of breast cancer cells by adipose and bone microenvironment. **K. Wang**, S.H. Wan, W. Wang, T. Wang, Y. Zhang (Chongqing, P.R. China) (20')

microRNAs

Room A, 18:00-19:30
Thursday, September 20

Chair Persons: C. Cava, Y. Huang, V. Sorrenti

140. miRNAs regulating pathway cross-talk in breast cancer subtypes. **C. Cava**, G. Bertoli, I. Castiglioni (Milan, Italy) (20')
172. MicroRNA-374c-5p regulates TGF- β 1 induced epithelial-mesenchymal transition and migration of cervical cancer cell. **Y. Huang**, H. Huang, M. Li, X. Zhang, Y. Liu, Y. Wang (Guangdong, P.R. China) (20')
185. Heme oxygenase-1 inhibitors to overcome imatinib resistance in chronic myeloid leukemia. **V. Sorrenti** (Catania, Italy) (20')
142. A methodological approach to screen the miRNAs in PUBMED and KMPLLOT database associated with triple negative breast cancer and identify the potential mRNA targets. **Y.N. Zhao**, Q. Li, M.N. Wang, X.B. Liu, Y.L. Luo (Chengdu, PR China) (15')
217. The role of microRNAs in muscle stem cell during human aging. **E.S. Di Filippo** (Chieti, Italy) (15')

IMMUNOLOGY/MOLECULAR MEDICINE

Room B, 09:00-11:00
Thursday, September 20

Chair Persons: L. Vannucci, H. Okamura, M. Ferrante

161. Microbiome can influence the thymus immune environment. **L. Vannucci**, F. Caja, D. Stakheev, P. Tenti, P. Lukac, O. Chernyavskiy, D. Vondracek, P. Makovicky, L. Rajsiglova, T. Hudcovic, J. Dvorak, P. Sima, H. Kozakova (Prague, Czech Republic; Komarno, Slovak Republic) (25')
137. IL-18 in NK-cell-based cancer immunotherapy. W. Li, Y. El-Darawish, K. Yamanishi, H. Yamanishi, **H. Okamura** (Nishinomiya; Hirakata, Japan) (25')
180. Environmental determinants, biomarkers and chronic disease. **M. Ferrante**, S.S. Signorelli, C. Copat, A. Cristaldi, P. Zuccarello, A. Grasso, M. Fiore, G. Oliveri Conti (Catania, Italy) (25')
199. Psoriasis: Evaluation of depression in patients treated with biological drugs. **M.C. Petralia**, S. Castellano, M. Coco, R. Fassari, S. Platania, R. De Pasquale, S. Di Nuovo (Catania, Italy) (20')
232. The Bio Immune(G)ene medicine and the use of miRNAs to regulate EBV its implications in oncology. **M.C. Parés Santilari** (Barcelona, Spain) (25')

CLINICAL ONCOLOGY/MOLECULAR ONCOLOGY

Room B, 11:30-13:05
Thursday, September 20

Chair Persons: B.C. Valdez, R. Tsunedomi

221. Epigenetic modification enhances the efficacy of busulfan and cyclophosphamide in acute myeloid leukemia. **B.C. Valdez**, X. Tang, B.S. Andersson (Houston, TX, USA; Suzhou, P.R. China) (25')
127. *RAB3B* was identified as a gene involved in characteristics of induced cancer stem-like sphere cells. **R. Tsunedomi**, K. Yoshimura, S. Kanekiyo, Y. Tokumitsu, S. Tomochika, M. Iida, N. Suzuki, S. Takeda, S. Yamamoto, S. Yoshino, S. Hazama, T. Ueno, H. Nagano (Ube; Tokyo; Okayama, Japan) (25')
118. Defeating cancer by micro-environment genetic engineering. **M. Al Zoubi**, M. Lisanti, H. Arafat (Irbid, Jordan; Sandford, UK; Philadelphia, PA, USA) (15')
143. Differential diagnostic value of PET/CT between renal carcinoma and renal lymphoma. **S. Zhu**, C. Shen, S. Duan, R. Shao, X. Cui, X. Ma (Chengdu, P.R. China) (15')
144. The differential diagnostic value of PET/CT radiomics texture features on primary and metastatic liver carcinoma. **X. Cui**, Y. Liu, F. Pang, Y. Dong, S. Zhu, X. Ma (Chengdu, P.R. China) (15')

PHARMACOLOGY/IMMUNOTHERAPY

Room B, 16:00-17:30
Thursday, September 20

Chair Persons: E. Agostinelli, M.S. Basile

197. Bovine serum amine oxidase and spermine cause apoptosis in cancer cells detected by flow cytometry, real time RT-PCR and proteomic analyses. **E. Agostinelli**, A. Finotti, Y. Kanamori, J. Gasparello, S. Ohkubo, F. Timeus, S. Merali, R. Gambari (Rome; Ferrara, Italy; Philadelphia, PA, USA) (30')
163. Anticancer properties of nitric-oxide modified lopinavir in human glioblastoma cells. **M.S. Basile**, E. Mazzon, F. Corsico, T. Krajnovic, D. Draca, P. Fagone, S. Mamma, F. Nicoletti, S. Mijatovic, D. Maksimovic-Ivanic (Belgrade, Serbia; Catania; Messina, Italy) (15')
164. A role for macrophage migration inhibitory factor (MIF) in discoid lupus erythematosus. **G. Campo**, E. Piombino, P. Fagone, K. Mangano, E. Cavalli, F. Nicoletti, R. Caltabiano, R. De Pasquale (Catania; Messina, Italy) (15')
165. Genomics of neuroblastoma predict their clinical responses to immunotherapy. **S.D. Lombardo**, E. Mazzon, M. Presti, S. Mamma, S. Candido, M. Libra, P. Bramanti, F. Nicoletti (Catania; Messina, Italy) (15')
220. Targeting metabolic vulnerabilities to treat Shh medulloblastoma. **L. Di Magno**, S. Manni, F. Di Pastena, S. Coni, S.M. Serrao, E. Agostinelli, G. Canettieri (Rome, Italy) (15')

MOLECULAR ONCOLOGY/MOLECULAR MEDICINE

Room B, 18:00-19:30
Thursday, September 20

Chair Persons: H. Osawa, S.M. Ferrari

175. TAS-102 plus bevacizumab with metastatic colorectal cancer in salvage line. **H. Osawa** (Tokyo, Japan) (20')
226. Antitumor activity of vandetanib in anaplastic thyroid cancer *in vitro* and *in vivo*. **S.M. Ferrari**, P. Fallahi, I. Ruffilli, G. Elia, S.R. Paparo, A. Antonelli (Pisa, Italy) (20')
227. Th1 chemokine secretion by vanadium pentoxide in primary dermal fibroblasts. **P. Fallahi**, S.M. Ferrari, F. Ragusa, C. Caruso, G. Guglielmi, R. Foddìs, A. Antonelli (Pisa, Italy) (20')
183. The importance of HPV transcription status detection in a case of head and neck cancer. **G. Ilardi**, D. Russo, S. Varricchio, F. Merolla, V. Napolitano, R.M. Di Crescenzo, M. Mascolo, S. Staibano (Naples; Campobasso, Italy) (15')
111. STAT5 transcriptional networks: Towards biomarker discovery. **E. Katsantoni** (Athens, Greece) (15')

EXPERIMENTAL THERAPEUTICS

Room A, 09:00-11:00
Friday, September 21

Chair Persons: T. Eckschlager, S.N. Karagiannis, C.S. Gondi

146. Apoferritin as a nanoscaled delivery vehicle for anticancer agents. T. Cerna, J. Hrabeta, Z. Heger, S. Dostalova, R. Indra, V. Adam, M. Stiborova, **T. Eckschlager** (Prague; Brno, Czech Republic) (25')
159. Novel antibody therapeutic strategies for breast cancer. **S.N. Karagiannis** (London, UK) (25')
113. Circular dumbbell RNAs loaded with miR34a: A novel anti-angiogenic approach. M. Gnanamony, **C.S. Gondi** (Peoria, IL, USA) (20')
173. Vitamin D receptor gene and its regulation by all-trans-retinoic acid in normal blood cells and in leukemic blasts. **E. Marcinkowska** (Wroclaw, Poland) (20')
174. Combination of temozolomide with dexamethasone reinforces the changes in normal brain tissue structure and composition. A.Y. Tsidulko, C. Bezier, G. De la Bourdonnaye, A.V. Suhovskih, G.M. Kazanskaya, S.V. Aidagulova, **E.V. Grigorieva** (Novosibirsk, Russia; Paris, Toulouse, France) (15')
147. Antitumor effect and mechanism of chlorotoxin-targeted onconase. **X. Wang**, R. Zhao (Inner Mongolia, P.R. China) (15')

AUTOPHAGY/MOLECULAR ONCOLOGY

Room A, 11:30-13:00
Friday, September 21

Chair Persons: A.K. Larsen, F. Timeus

200. Autophagy dependence of angiokinase inhibitors in colorectal cancer (CRC). L. Louadj, P. Mésange, M. Sabbah, **A.K. Larsen** (Paris, France) (25')
196. Hemophagocytic lymphohistiocytosis in pediatric patients: A single centre experience. **F. Timeus**, E. Barisone, E. Vassallo, I. Bini, S.D. Asaftei, F. Sismondi, E. Sieni, F. Fagioli (Torino; Firenze, Italy) (25')
133. Estrogen metabolism in schistosoma haematobium-associated bladder cancer. **M.C. Botelho** (Porto, Portugal) (20')
247. Plasma cell-derived microparticles trigger thrombin generation and induce a procoagulant shift of endothelial cells: New insights into the pathogenesis of thrombosis in multiple myeloma. L. Papageorgiou, S. Salta, A. Rousseau, M. Grusse, H. Mokrani, P. Van Dreden, A.K. Larsen, I. Elalamy, **G.T. Gerotziafas** (Paris; Gennevilliers, France) (20')

EXPERIMENTAL THERAPEUTICS

Room A, 16:00-17:30
Friday, September 21

Chair Persons: R.M. Hoffman, H. Modjtahedi

167. Patient-derived orthotopic xenografts: Better mimic of metastasis than subcutaneous xenografts. **R.M. Hoffman** (San Diego, CA, USA) (30')
160. Biological and clinical significance of wild-type EGFR, EGFR ligands and putative cancer stem cell biomarkers in colorectal cancer. S.A. Khelwatty, S. Essapen, I. Bagwan, A.M. Seddon, **H. Modjtahedi** (Kingston; Guildford, UK) (30')
238. The Tim-3-galectin-9 pathway determines the capability of human malignant cells to escape host immune surveillance. I.M. Yassinska, S.S. Sakhnevych, I. Goncalves Silva, B.F. Gibbs, Y.A. Ushkaryov, R. Hussain, G. Siligardi, W. Fiedler, E. Fasler-Kan, **V.V. Sumbayev** (Kent; Didcot, UK; Hamburg, Germany; Bern, Switzerland) (30')

THERAPEUTICS/TOXICOLOGY

Room A, 18:00-19:30
Friday, September 21

Chair Persons: M. Krstic-Demonacos, A. Tsatsakis, A. Zaravinos

245. Regulation of autophagy, endoplasmic reticulum and unfolded protein response in acute lymphoblastic leukemia by glucocorticoids. S. Sudsaward, T. Limjindaporn, P.T. Yenchitsomanus, L. Mutti, C. Demonacos, **M. Krstic-Demonacos** (Salford; Manchester, UK; Bangkok, Thailand; Philadelphia, PA, USA) (25')
192. Modern toxicology revolves towards assessing and promoting human and environmental health from major anthropogenic pressures and simulation of real life associated drivers from combined long term exposures. **A. Tsatsakis** (Heraklion, Greece) (25')
186. Association of different cancer drivers and kataegis with distinct cytolytic subgroups in colorectal cancer. **A. Zaravinos**, K. Roufas (Nicosia, Cyprus) (20')
189. The roles of hyaluronan/RHAMM and their respective interactions along the insidious pathways of fibrosarcoma progression. **D. Nikitovic**, A. Tsatsakis, D.A. Spandidos, G. Tzanakakis (Heraklion, Greece) (20')

BIOMARKER DISCOVERY/CLINICAL ONCOLOGY

Room B, 09:00-11:00
Friday, September 21

Chair Persons: E. Karteris, E. Katsuta

187. Applications of liquid biopsies for biomarker development in lung cancer. D. Chudasama, C. Sisu, M. Hall, V.B. Anikin, **E. Karteris** (London, UK) (30')
136. High expression of H2AX predicts early recurrence in advanced stage breast cancer. **E. Katsuta**, M. Ouchi, T. Ouchi, K. Takabe (Buffalo, NY, USA) (30')
176. Cytogenetic studies of pediatric solid tumors. **E. Fasler-Kan**, N. Aliu, S.M. Berger (Bern, Switzerland) (15')
115. Resveratrol's effect on non-alcoholic fatty liver disease (NAFLD). **M. Theodotou**, K. Fokianos, D. Moniatis, R. Kadlenic, A. Chrysikou, A. Aristotelous, A. Mouzouridou, J. Diakides, E. Stavrou (Limassol; Nicosia, Cyprus) (15')
135. CSF3R mutations are frequently associated with abnormalities of RUNX1, CBFβ, CEBPA and NPM1 genes in acute myeloid leukemia. Y. Zhang, F. Wang, X. Chen, Y. Zhang, M. Wang, H. Liu, P. Cao, X. Ma, T. Wang, J. Zhang, X. Zhang, D. Lu, P. Lu, **H. Liu** (Langfang; Beijing, P.R. China) (15')
141. Quantitative proteomics analysis of cerebrospinal fluid from patients with extranodal NK-/T-cell lymphoma of nasal-type for potential diagnosis. **Q. Li**, Y. Zhao (Chengdu, P.R. China) (15')

MOLECULAR MEDICINE/MOLECULAR ONCOLOGY

Room B, 11:30-13:15
Friday, September 21

Chair Persons: K. Nordlind, M. Danilenko

130. Atopic dermatitis and stress. **K. Nordlind** (Stockholm, Sweden) (25')
188. Synergistically acting combinations of natural phenolic compounds for the treatment of acute myeloid leukemia. A. Trachtenberg, S. Pesakhov, S. Muduli, D. Fishman, K. Sydorik, M. Cybulski, **M. Danilenko** (Beer Sheva, Israel; Warsaw, Poland) (25')
139. Proteomics insights into complexity and molecular heterogeneity of bone marrow failure disorders. **A. Alaiya**, Z. Shinwari, H. Alzahrani, T. Owaidah, F. AlMohareb, F. Al Sharif, R. AlNounou, W. Rasheed, R. ElFakih, A. Hanbali, M. Shaheen, F. Alfraih, H. Shahrukh, M. Dasouki, N. Chaudhri, O.A. Syed, M. Aljurf (Riyadh, Saudi Arabia) (25')
138. Histone acetylation and neurogenesis are associated with hippocampal abnormalities in interleukin-18-deficient mice. **K. Yamanishi**, T. Hashimoto, K. Ikubo, K. Mukai, N. Uwa, Y. El-Darawish, W. Li, Y. Watanabe, H. Yamanishi, H. Okamura, H. Matsunaga (Nishinomiya; Hirakata, Japan) (15')
257. The angiogenic potential of aggressive osteosarcoma is regulated by AUF1 through targeting VEGF-A. **H.H. Al Khalaf** (Riyadh, Saudi Arabia) (15')

MOLECULAR MEDICINE

Room B, 16:00-17:30
Friday, September 21

Chair Persons: G. Pissas, R. Tabola

212. Facing endoplasmic reticulum stress-induced damage. **G. Pissas** (Volos, Greece) (20')
214. A novel regulatory function of CDKN1A/p21 in TNF α -induced matrix metalloproteinase 9-dependent migration and invasion of triple-negative breast cancer cells. M. Zaremba-Czogalla, A. Hryniewicz-Jankowska, **R. Tabola**, M. Nienartowicz, K. Stach, J. Wierzbicki, R. Cirocchi, P. Ziolkowski, S. Tabaczar, K. Augoff (Wroclaw, Poland) (20')
215. The association between HOTAIR polymorphisms and cancer susceptibility: An updated systematic review and meta-analysis. L. Min, X. Mu, A. Tong, Y. Qian, C. Ling, T. Yi, **X. Zhao** (Chengdu, P.R. China) (20')
222. Interaction of hematopoietic stem cells and glioblastoma cells stimulated by TGF- β 1 *in vitro*. **M.K. Korneyko**, A.I. Ponomarenko, I.A. Lyakhova, Y.I. Zayats, S.V. Zaitsev, I.S. Bryukhovetskiy (Vladivostok, Russia) (15')
224. Electron transfer in health and disease. **A.M. Kyriakopoulos**, N. Khoury, S. Baliou, V. Zoumpourlis (Pireus; Athens, Greece) (15')

MOLECULAR ONCOLOGY/microRNAs

Room B, 18:00-19:30
Friday, September 21

Chair Persons: E. Rizos, V. Zoumpourlis

114. The low cancer risk in patients suffering from schizophrenic spectrum disorder. The possible role of microRNAs. Future medication strategies. **E. Rizos**, N. Siafakas, E. Skourti, C. Papageorgiou, J. Tsoporis, Th. Parker, D.A. Spandidos, E. Katsantoni, V. Zoumpourlis (Athens, Greece; Toronto, Canada; Heraklion, Greece) (20')
252. The potential use of CRISPR systems regulating the expression of tropomyosin-1 to change the F-actin-based inflammatory response of coronary artery endothelium. **M. Gagat**, D. Grzanka, W. Zielińska, M. Hałas-Wiśniewska, A. Krajewski, A. Grzanka (Bydgoszcz, Poland) (20')
253. Cyclin F - a new potential melanoma regulator - perspectives. **A. Krajewski**, M. Gagat, M. Hałas-Wiśniewska, A. Żuryń, D. Grzanka, A. Grzanka (Bydgoszcz, Poland) (15')
134. miR-137 modulates the expression of the DNA mismatch repair protein MSH2. **F. Duraturo**, R. Liccardo, M. De Rosa, P. Izzo (Naples, Italy) (20')
117. Taurine derivatives exhibit therapeutic effect against various cancers. **S. Baliou**, M. Nagl, A.M. Kyriakopoulos, V. Zoumpourlis (Athens, Greece; Innsbruck, Austria; Pireas, Greece) (15')

INFLAMMATION AND CHRONIC DISEASES

Organized by **S.S. Signorelli**

Room A, 09:00-11:00

Saturday, September 22

Chair Persons: S.S. Signorelli, G. Lessiani, M. Libra

204. Role of the transcription factor yin yang 1 in cancer. **S. Vivarelli**, S. Candido, R. Salemi, L. Falzone, M. Libra (Catania, Italy) (20')
203. Effects of intermolecular bond depletion of NGAL/MMP9 complex on MMP9 activation and tumor invasiveness. **S. Candido**, L. Falzone, R. Salemi, M. Libra (Catania, Italy) (20')
178. Platelet-derived microparticles (MPs), pro-thrombinase-induced clotting times and phospholipids in a cohort of patients with deep vein thrombosis: A pilot study. **S.S. Signorelli**, G. Oliveri Conti, M. Fiore, F. Cangiano, P. Zuccarello, M. Ferrante (Catania, Italy) (20')
179. Diabetes and osteoporosis: Common pathophysiological pathways and biochemical markers. **A. Gaudio**, A. Xourafa, R. Rapisarda, P. Castellino (Catania, Italy) (15')
207. Biomarkers for thrombotic venous disease: Useful tool in decision making. **G. Lessiani** (Pescara, Italy) (15')
206. Analysis of MMP-9 serum levels in melanoma patients with circulating-free DNA BRAFV600E mutation. **L. Falzone**, R. Salemi, S. Candido, A. Scalisi, M. Libra (Catania, Italy) (15')
205. Circulating-free DNA PI3KCAH1047R mutation is detected in melanoma patients treated with both BRAF and MEK inhibitors. **R. Salemi**, L. Falzone, S. Candido, D. Mallardo, G. Madonna, P. Ascierto, M. Libra (Catania; Naples, Italy) (15')

IMMUNOLOGY/TOXICOLOGY

Room A, 11:30-13:15

Saturday, September 22

Chair Persons: F. Nicoletti, V. Rapisarda

208. Role for macrophage migration inhibitory factor in autoimmune diseases. P. Fagone, I. Stojanovic, S. Stosic-Grujicic, **F. Nicoletti** (Catania, Italy; Belgrade, Serbia) (20')
198. Role of tetraspanin 32 (TSPAN32) in the modulation of T cell-mediated immune response. **F. Corsico**, E. Mazzon, A. Bramanti, S. Mammana, E. Cavalli, M.S. Basile, M.C. Petralia, K. Mangano, F. Nicoletti, P. Fagone (Catania, Italy) (20')
209. Immune-escape mechanisms in uveal melanoma: an integrative analysis. **P. Fagone**, K. Mangano, S. Mammana, M.S. Basile, E. Cavalli, F. Corsico, M. Reibaldi, F. Nicoletti (Catania; Messina, Italy) (15')
229. Monoclonal gammopathy of undetermined significance and occupational exposure: Study of workers of a dump chemical waste. C. Ledda, E. Vitale, F. Vella, A. Marconi, S. Matera, D. Cinà, M. Barbagallo, L. Rapisarda, **V. Rapisarda** (Catania, Italy) (20')
228. Prevalence of antinuclear factor in a population exposed to fluoro-edenite fibers: The case of Biancavilla. **C. Ledda**, C. Loreto, E. Vitale, V. Filetti, P. Senia, A. Marconi, D. Cinà, A. Musumeci, V. Ricceri, V. Rapisarda (Catania; Biancavilla, Italy) (15')
246. Plasma thioredoxin reductase and myeloperoxidase levels in acquired aortic valve stenosis patients. J. Lurins, D. Lurina, G. Krievina, **V. Mackevics**, P. Tretjakovs, A. Lejnicks, S.S. Signorelli (Riga, Latvia; Catania, Italy) (15')

THERAPEUTICS/VIRUSES

Room A, 16:00-17:30
Saturday, September 22

Chair Persons: T. Nakamura, E.T. Detorakis

124. IL-1 β induced local inflammation may enhance the progression of epithelial cell carcinoma by recruited macrophages in transgenic mice. **T. Nakamura** (Kurashiki, Japan) (30')
168. Human papilloma virus in ophthalmic disease: Enemy ante portas. **E.T. Detorakis** (Crete, Greece) (30')
125. MYC-related microRNA signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways. **G. Malpeli**, S. Barbi, G. Tosadori, C. Greco, S. Zupo, S. Pedron, M. Brunelli, A. Bertolaso, M.T. Scupoli, M. Krampera, P. Takam Kanga, C.M. Croce, G.A. Calin, A. Scarpa, A. Zamò (Verona; Genoa; Torino, Italy; Columbus, OH; Houston, TX, USA) (30')

BRAIN TUMORS/CLINICAL ONCOLOGY

Room A, 18:00-19:30
Saturday, September 22

Chair Persons: S. Asuthkar, K.K. Velpula

126. Defining the role of B7-H3 on chemotaxis and angiogenesis regulation in medulloblastoma. I.J. Purvis, M.R. Guda, S. Venkataraman, R. Vibhakar, P.M. Yau, B.S. Imai, I. Alexandrov, M. Mackenzie, J. Regan, A.J. Tsung, K.K. Velpula, **S. Asuthkar** (Peoria, IL; Aurora, CO; Urbana-Champaign, IL; Natick, MA, USA) (25')
132. Delineating the role of metabolism in controlling glioblastoma progression. M.R. Guda, S. Asuthkar, C.P. Smith, A.J. Tsung, **K.K. Velpula** (Peoria, IL, USA) (20')
166. A computational model for the prevision of outcome in the treatment of glioblastoma multiforme patients. **M. Presti**, E. Mazzon, S.D. Lombardo, F. Corsico, P. Fagone, M.C. Petralia, S. Candido, M. Libra, F. Nicoletti, P. Bramanti (Catania; Messina, Italy) (15')
234. Biomarkers and liver cancer process. **O. Topolcan**, R. Kucera, M. Karlikova, S. Svobodova, R. Fuchsova, V. Simanek, J. Kinkorova, O. Fiala, V. Treska (Pilsen, Czech Republic) (15')
235. Matrix metalloproteinases as biomarkers for colorectal cancer. **M. Karlikova**, O. Topolcan, R. Kucera, V. Simanek, J. Kinkorova, V. Karnos Jr., M. Curillova, V. Karnos (Pilsen, Czech Republic) (15')

MOLECULAR ONCOLOGY/MEDICINE

Room B, 09:00-11:00
Saturday, September 22

Chair Persons: S. Gurzu, L.M. Junie

201. Gastrointestinal cancer and tumor microenvironment. **S. Gurzu**, L. Baniias, T. Bara, Z. Fulop, I. Simu, P. Simu, I. Jung (Tirgu-Mures, Romania) (20')
202. Malignant melanoma: Immunohistochemical evaluation of tumor microenvironment. **I. Jung**, D. Milutin, S. Mocan, M.A. Beleaua, S. Gurzu (Tirgu-Mures, Romania) (20')
184. The carbapenemase codifying gene detection in *Klebsiella pneumoniae* strains. M. Tompa, S.L. Pandrea, M.I. Ciontea, E. Chiorean, R. Tompa, **L.M. Junie** (Cluj-Napoca, Romania) (20')
219. Solubility improved germline-humanized anti-EGFR single chain antibody. **K. Veisi**, Y. Safdari (Tehran; Gorgan, Iran) (20')
145. Carbon nanotube based label-free electrochemical nanosensors for tumor associated KRAS status determination. **A.S. Babenka**, H.V. Grushevskaya, N.G. Krylova, I.V. Lipnevich (Minsk, Belarus) (20')
236. Overexpression of FoxO3a is associated with glioblastoma progression and predicts poor patient prognosis. **L. Ren**, J. Xing, Z. Wei, Y. Lin (Shanghai, P.R. China) (20')

MOLECULAR ONCOLOGY/MEDICINE

Room B, 11:30-13:15
Saturday, September 22

Chair Persons: D.P. Vageli, V. Bravou

121. *In vivo* topical application of BAY 11-7082 prevents the acidic bile-induced mRNA and miRNA oncogenic phenotypes, in exposed murine hypopharyngeal mucosa. **D.P. Vageli**, S.G. Doukas, C.T. Sasaki (New Haven, CT, USA) (20')
102. Crosstalk between the IPP complex and oncogenic KRAS in lung cancer. S. Nikou, M. Arbi, G.T. Stathopoulos, **V. Bravou** (Patra, Greece) (20')
248. Clinicopathological features of women affected by uterine Malignant Mixed Mullerian Tumors (MMMTs). **A. Semczuk**, D. Vasilevska, A. Wróbel, M. Bogusiewicz, A. Kamińska, A. Pyra, T. Rechberger (Lublin, Poland; Vilnius, Lithuania; Nowa Deba, Poland) (20')
233. Tumors and wound microenvironments: Biological similarities and pharmacological modulation. **P. Gál**, K. Smetana Jr. (Košice, Slovak Republic; Prague, Czech Republic) (15')
122. Capability of curcumin in preventing the bile reflux-induced NF- κ B-related mRNA oncogenic phenotype in human hypopharyngeal cells. D.P. Vageli, **S.G. Doukas**, T. Spock, C.T. Sasaki (New Haven, CT, USA) (15')
259. A digital pathology approach to head and neck squamous cell carcinomas. **F. Merolla**, D. Russo, G. Iardi, S. Varricchio, F. Martino, N. Brancati, M. Cervasio, S. Pignatiello, S. Staibano (Campobasso; Naples, Italy) (15')

4TH WORKSHOP ON PAEDIATRIC VIROLOGY

Organized by the **Paediatric Virology Study Group**

Room B, 16:00-17:30

Saturday, September 22

Chair Persons: T. Dalianis, I.N. Mamas

148. Human papillomavirus (HPV) prevalence in youth at a youth clinic after the initiation of HPV-catch up vaccination in comparison to previously obtained HPV prevalence in the same clinic and to that in high school youth in Sweden. N. Grün, J. Du, A. Ährlund-Richter, L. Mirzaie, T. Ramqvist, **T. Dalianis** (Stockholm, Sweden) (30')
151. Exploring effective interventions to increase adolescents' vaccination against human papillomavirus (HPV). **I.N. Mamas**, M. Theodoridou, G. Sourvinos, D.A. Spandidos (Crete; Athens, Greece) (20')
149. Laryngeal HPV infection in children: A review of management and treatment of juvenile onset recurrent respiratory papillomatosis. **S.G. Doukas** (New Haven, CT, USA) (20')
150. The involvement of human papilloma virus (HPV) in eye disorders in neonates and children: An update. **V. Achtsidis**, E. Kozanidou (Athens; Piraeus, Greece) (20')

4TH WORKSHOP ON PAEDIATRIC VIROLOGY

Organized by the **Paediatric Virology Study Group**

Room B, 18:00-19:30

Saturday, September 22

Chair Persons: M. Theodoridou, P. Thiagarajan

152. Overview of influenza vaccination in children. **M. Theodoridou** (Athens, Greece) (20')
153. Antiviral drugs in the clinical management of children with influenza. **P. Thiagarajan** (Douglas, Isle of Man) (25')
230. Prevention and management of influenza in childhood: The effect of probiotics. **P. Korovessi** (Athens, Greece) (15')
154. Epidemiology of influenza types and subtypes in childhood. **A. Melidou** (Thessaloniki, Greece) (15')
155. Radiology issues of influenza in children. **G. Papaioannou** (Athens, Greece) (15')

POSTERS (Poster viewing during the entire congress)

104. Evaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving bortezomib-based therapy for multiple myeloma. X. Zhou, J. Wang, J. Xia, F. Cheng, J. Mao, J. Zhu, **H. Guo** (Wuxi, P.R. China)
105. Family haploidentical donor-derived cytokine-induced killer cells biotherapy combined with bortezomib in two relapsed patients with multiple myeloma in a non-allogeneic transplant setting. X. Zhou, J. Zhu, H. Sun, L. Shao, M. Xu, **H. Guo** (Wuxi, P.R. China)
107. Mab's to human rotavirus after immunization by bovine rotavirus. **V. Sologub**, I. Koromyslova, K. Hametova (Moscow, Russia)
110. The anti-tumorigenic actions of the Na⁺/K⁺ ATPase inhibitor istaroxime in prostate cancer cells. **S. Alkahtani**, S. Alafiri, N. Zacharopoulou, M.J. Stagno, C. Alevizopoulos, E. Schmid, C. Stourmaras (Heraklion, Greece; Riyadh, Saudi Arabia; Tuebingen, Germany; Yverdon-les-Bains, Switzerland)
112. E6 and E7 HPV induce DAPK1 and CADM1 promoter methylation. K. Chalertpet, J. Sukbhattee, I. Nuchcharoen, P. Phumcharoen, A. Mutirangura, **P. Yanatsaneejit** (Bangkok, Thailand)
119. TBX2 expression is associated with platinum-sensitivity of ovarian serous carcinoma. **H. Matsubara**, T. Fukuda, M. Shimomura, R. Tasaka, M. Yamauchi, T. Yasui, T. Sumi (Osaka; Izumiotsu; Kishiwada, Japan)
120. Expression of UCP2 is associated with sensitivity to platinum-based chemotherapy for ovarian serous carcinoma. **Y. Inoue**, T. Fukuda, M. Kawanishi, M. Shimomura, T. Wada, M. Yamauchi, T. Yasui, T. Sumi (Osaka; Suita; Kashiwara, Japan)
123. Association between HLA class II alleles and suicidal behavior. **M.L. Vică**, G.Z. Nicula, L.M. Junie, C.V. Siserman, H.V. Matei (Cluj-Napoca, Romania)
131. Expression of HSF1 in astrocytic tumors. **A. Moutafidi**, V. Zolota, M. Assimakopoulou (Patras, Greece)
156. Participation of paediatric health professionals in the vaccination programme against seasonal influenza. **C. Koutsaftiki**, A. Papatheodoropoulou (Athens, Greece)
157. Myocarditis due to influenza: An update. **M. Calachanis** (Athens, Greece)
158. Influenza complications in PICU. **A. Papatheodoropoulou**, C. Koutsaftiki, J. Papadatos (Athens, Greece)
162. Immune remodeling of colon mucosa. P. Lukac, P. Tenti, F. Caja, D. Stakheev, O. Chernyavskiy, D. Vondracek, L. Rajsiglova, T. Hudcovic, H. Kozakova, J. Dvorak, P. Sima, P. Makovicky, **L. Vannucci** (Prague, Czech Republic; Komarno, Slovak Republic)
169. The 'Spanish' flu outbreak at the islands of Skyros, Euboea and Andros 100 years ago. **I.N. Mammas**, M. Theodoridou, D.A. Spandidos (Crete; Athens, Greece)
170. Biomarkers of oxidative stress in workers exposed to glyphosate. **C. Fenga**, A. Tsatsakis, M. Teodoro, M. Tzatzarakis, C. Costa (Messina, Italy; Crete, Greece)

177. Co-deregulated genes and their transcriptional regulators in colorectal cancer. N. Mastrogamvraki, **A. Zaravinos** (Nicosia, Cyprus)
181. Red blood cell membrane changes in streptozotocin-induced diabetic rats. **G.Z. Nicula**, M. Wankeu-Nya, C.V. Siserman, M.L. Vică, R. Munteanu, D. Rusu, A. Florea, H.V. Matei, Ș. Bâlici (Cluj-Napoca, Romania; Dschang, Cameroon)
182. The molecular basis of Lynch syndrome. **F. Duraturo**, R. Liccardo, M. De Rosa, P. Izzo (Naples, Italy)
190. Evaluation of the *in vivo* efficacy of immune-oncology drugs targeting immune checkpoint molecules using humanized knock-in mice. **Y. Guo**, C. Guo, Y. Shen (Beijing, P.R. China)
193. Study of the expression of 9-*O*-acetylated sialic acid by the *Macrobrachium rosenbergii* lectin in a cell line of squamous carcinoma of the oral cavity. **H. Sánchez Martínez**, D. Illescas Barbosa, V. Jiménez Castillo, C. Díaz Hernández, C.M. Félix Rosales, M.A. Pereyra Morales, M.C. Agundis Mata, A. Torres Rivera, B.X. Ávila Curiel, C.J. Solórzano Mata (Oaxaca; Mexico city, Mexico)
195. Vascular endothelial growth factor-A expression depends on the fibrosis degree of dominant uterine myoma tumour in reproductive-age women. **S.V. Aidagulova**, Y.V. Zenina, D.A. Solyanikov, I.O. Marinkin (Novosibirsk, Russia)
210. Case Study: A 4 year-old girl with HPV 6 infection. **S.P. Derdas**, S. Gerou, D.A. Spandidos (Heraklion; Thessaloniki, Greece)
211. SPARC and miR-29ab: Friends or foes in melanoma metastasis. J.R. Ferreres, A. Vinyals, E. Cabré, I. Pardo, J. Adria, J. Marcoval, **À. Fabra** (Barcelona, Spain)
213. Preconditioning of human renal epithelial cells with amino acid deprivation against endoplasmic reticulum stress. **G. Pissas**, T. Eleftheriadis, E. Karamitrou, S. Tsiogkas, K. Tsogka, I. Stefanidis (Volos, Greece)
218. Whole-exome analysis in osteosarcoma to identify genetic alterations for new molecular markers and possible therapeutic approaches. **S. Heinsohn**, W. Hassenpflug, R. Scheppenheim, S. Rutkowski (Hamburg, Germany)
223. G-CSF stimulates production of TGF- β in the focus of experimental glioblastoma in rats. **A.I. Ponomarenko**, M.K. Korneyko, I.A. Lyakhova, Y.I. Zayats, S.V. Zaitsev, I.S. Bryukhovetskiy (Vladivostok, Russia)
231. HPV infection and neonatal prematurity. **I.N. Mammas**, G. Sourvinos, D.A. Spandidos (Heraklion, Greece)
237. The microRNA signature obtained by massive sequencing can predict the response to systemic therapy in metastatic breast cancer patients. **A.D. Campos-Parra**, A.D. Martinez Gutierrez, O. Millan Catalan, R. Vazquez-Romo, F.I. Porras Reyes, E. Lopez Urrutia, C. Pirez-Plasencia (Ciudad de México, México)
239. Involvement of the CREB pathway in the radiation response of Ramos B lymphoma cells. S. Sancilio, **G. Stati**, L. Centurione, M.A. Centurione, M. Basile, R. Di Pietro (Chieti, Italy)
240. Expression and role of CREB/ATF family members in human Burkitt lymphoma. **M. Basile**, P. Vizzarri, R. Di Censo, P. Nicoli, G. Stati, S. Sancilio, R. Di Pietro (Chieti-Pescara, Italy)

241. HPV E6/E7 mRNA expression compared to HPV DNA in Greek population increases the specificity and positive predictive value of cervical cancer screening. **S.P. Derdas**, S.K. Archondakis, R.S. Oustambasidou, D.A. Spandidos (Heraklion; Athens, Greece)
242. Plant derived exosomal microRNAs: New therapeutic chances. L. Amodeo, **F.M. Pezzino**, **A. Russo**, L. Lo Cicero, D. Catalano, B. Ficili, A. Scarfia, S. Laudani, M.C. Di Bella, M. Nivea Terzo, F. Sinatra, F. Branca, S. Trivali (Catania, Italy)
243. Histopathologic risk factors for lymph node metastasis in patients with T1 colorectal cancer. **S. Noura**, A. Hamabe, T. Ogino, T. Tanida, S. Morita, Y. Tomimaru, H. Imamura, T. Iwazawa, K. Dono (Osaka, Japan)
244. HPV as an emerging risk factor in head and neck carcinomas: An additional vaccination target. **A. Zaravinos** (Nicosia, Cyprus)
250. miR-204-5p expression in cutaneous melanoma: Inhibition and target genes. **M.B. Aksenenko**, A.V. Komina, N.V. Palkina, R.N. Belonogov, T.G. Ruksha (Krasnoyarsk, Russia)
251. Evaluation of the importance of selected obesity-inflammation-tumor axis proteins in the group of patients with cancer of the endometrium. **M. Gagat**, P. Antosik, A. Klimaszewska-Wiśniewska, J. Józwicki, A. Grzanka, D. Grzanka (Bydgoszcz, Poland)
254. Genistein exerts antioxidant activity, modulates cell migration and angiogenesis-related gene expression. **V. Gálová**, L. Varinská, P. Gál (Košice, Slovak Republic)
255. Genistein improves skin flap viability in female rats. **T. Vasilenko**, I. Kováč, M. Novotný, P. Gál (Košice, Slovak Republic)
256. Thyroid hormone induces HEM45 expression to promote metastasis and angiogenesis in liver cancer. S.-L. Lin, **K.-H. Lin** (Taoyuan, Taiwan, R.O.C.)
258. Long-noncoding RNA-Linc00665 promotes prostate cancer progression by regulating autophagy. Y. Han, X. Zhang, H. Tian, M. Lu, Y. Li, J. Wu, H. Hu, **J. Zhou** (Xi'an, P.R. China)